# Shanghai Omni Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-omni-pharmaceutical-co

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.omni-pharma.com
- Latest round: Series D (Nov 19, 2024)
- Investors on record: 13

## About

Established in 2011 and based in Shanghai, China, Shanghai Omni Pharmaceutical Co., Ltd operates as an innovative pharmaceutical company that focuses on the development of respiratory preparation. The company has a proprietary design platform incorporating breathing apparatus. The company's marketing network includes hospitals, retail pharmacies and e-commerce platforms. Kai Zhang, the chairman of the company, was formerly the director of product development at IVAX Corporation. In November 2024, Shanghai Omni Pharmaceutical Co., Ltd closed a series D+ funding.

The company's main business is respiratory drug delivery technology and innovative drug research and development. Products include metered dose inhaler, dry powder inhaler, inhaled nebulizing solutions and nasal spry. The dry powder formulation project has been designated the National Key Science and Technology project, and received government support. Also, other projects have entered the clinical trial stage. Products can treat asthma and chronic obstructive pneumonia (COPD).

The company generates revenue by providing respiratory preparation and related products.

## Funding rounds

- Series D, Nov 19, 2024 — Oriza Holdings, Shanghai Industrial Investment (Holdings) Company Limited
- Series D, Dec 27, 2021 — Bank of China Group Investment, Shanghai Zhangke Lingyi Investment Management Co., LTD, Zhongxin Capital, Shanghai Healthcare Capital, Origins Capital, Taikun Fund
- Series C, Oct 19, 2017 — Vivo Capital, SDIC Venture Capital
- Series A, Sep 22, 2015 — Kleiner Perkins, Lilly Asia Ventures, 5Y Capital
- Series A, Jun 2, 2014 — Kleiner Perkins

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series C
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series C
- Bank of China Group Investment — Series D
- Shanghai Zhangke Lingyi Investment Management Co., LTD — Series D
- Zhongxin Capital — Series D
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series D
- Origins Capital (https://capitalatlas.ai/funds/origins-capital) — Series D
- Taikun Fund — Series D
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series D
- Shanghai Industrial Investment (Holdings) Company Limited — Series D